{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Correlation of peripheral CD34+ cell count with graft content of CD34+ cells assessed using Spearman correlation.","groups":[{"description":"Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \\>= 8 x 10\\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\\< 2 x 10\\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.\n\nplerixafor: Given SC\n\nfilgrastim: Given SC\n\netoposide: Given IV\n\nleukapheresis: Undergo apheresis","id":"OG000","title":"Treatment (Stem Cell Supermobilization)"}],"populationDescription":"No data collected for this outcome due to low accrual","reportingStatus":"POSTED","timeFrame":"Up to 28 days post treatment","title":"Correlation of Peripheral CD34+ Cell Count With Graft Content of CD34+ Cells","type":"SECONDARY"}